Post-translational protein modification of amino acid 330 of aldolase a protein and its mutant for anti-tumor application

By using Prime-Editing technology, the lysine at position 330 of aldolase A was mutated to arginine to prepare an aldolase A protein mutant, which solved the problem of the lack of post-translational modification mechanism of aldolase A and achieved effective regulation of tumor cells and safe tumor treatment.

CN119432823BActive Publication Date: 2025-10-17XIAMEN LUSHENGHENG BIOTECHNOLOGY CO LTD
2 Cites 0 Cited by

Patent Information

Application Number
CN202411620215.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-11-13
Publication Date
2025-10-17
Estimated Expiration
2044-11-13

AI Technical Summary

Technical Problem

The existing technology lacks an effective post-translational modification mechanism of aldolase A to regulate tumor cell growth, resulting in problems of drug resistance and toxic side effects in traditional tumor treatment methods.

Method used

Through Prime-Editing technology, the lysine at position 330 of aldolase A is mutated to arginine to prepare an aldolase A protein mutant, regulate its ubiquitination and acetylation modifications, and develop targeted tumor therapeutic drugs.

Benefits of technology

It significantly reduces the growth rate of malignant breast cancer and malignant melanoma cells in mice, demonstrates excellent anti-tumor activity, reduces the impact on normal cells, and improves the safety and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to the field of biotechnology, in particular to an application of post-translational protein modification of aldehyde dehydrogenase A protein 330 amino acids and mutant. The aldehyde dehydrogenase A protein mutant is obtained by substitution of the amino acid sequence shown in SEQ ID No. 1, and the lysine at position 330 is substituted by arginine. The present application proves by experiment that the aldehyde dehydrogenase A protein mutant can significantly reduce the growth rate of mouse malignant breast cancer cells 4T1 and mouse malignant melanoma cells B16-F10 in the mouse subcutaneous, and exhibits excellent anti-tumor activity. A new tumor treatment method is created, and the technical gap in the field is filled.
Need to check novelty before this filing date? Find Prior Art